Related references
Note: Only part of the references are listed.Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption
Justin J. Wilkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism
Fernanda S. Spies et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Tuberculosis in poorly controlled type 2 diabetes: Altered cytokine expression in peripheral white blood cells
Blanca I. Restrepo et al.
CLINICAL INFECTIOUS DISEASES (2008)
Extensively Drug-Resistant Tuberculosis in the United States, 1993-2007
N. Sarita Shah et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies
Christie Y. Jeon et al.
PLOS MEDICINE (2008)
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
Ian M. Rosenthal et al.
PLOS MEDICINE (2007)
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis
Deepak Almeida et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis
Hye-Ryoun Kim et al.
CLINICAL INFECTIOUS DISEASES (2007)
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis
Bachti Alisjahbana et al.
CLINICAL INFECTIOUS DISEASES (2007)
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin
Marc Weiner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears
A. H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis:: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
Radha K. Shandil et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth
Tawanda Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Amikacin-induced nephropathy: Is there any protective way?
Kubra Kaynar et al.
RENAL FAILURE (2007)
Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis
Kwok C. Chang et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Neel R. Gandhi et al.
LANCET (2006)
Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes
Hanneke M. J. Nijland et al.
CLINICAL INFECTIOUS DISEASES (2006)
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients
Justin J. Wilkins et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance
T Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
M Kinzig-Schippers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol
R Colangeli et al.
MOLECULAR MICROBIOLOGY (2005)
Isoniazid pharmacokinetics-pharmaco dynamics in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
T Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Mycobacterial efflux pumps and chemotherapeutic implications
M Viveiros et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene
VR Gordeuk et al.
BLOOD CELLS MOLECULES AND DISEASES (2003)
Association of pulmonary tuberculosis with increased dietary iron
IT Gangaidzo et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis
M Zhu et al.
PHARMACOTHERAPY (2001)
Share Paper
